Table 3.

Association between VEGF −460T/C, 405G/C, and 936C/T and OS in patient subgroups defined by histology and disease stage

GenotypeAdenocarcinoma
Squamous carcinoma
Lymph node negative
Lymph node positive/metastatic
AHR* (95% CI), PAHR* (95% CI), PAHR* (95% CI), PAHR* (95% CI), P
OS
VEGF −460T/C
    TTReferenceReferenceReferenceReference
    TC1.34 (0.90-1.98), 0.150.94 (0.39-2.28), 0.890.85 (0.44-1.66), 0.641.32 (0.89-1.95), 0.17
    CC1.24 (0.78-1.97), 0.371.32 (0.44-3.95), 0.620.24 (0.03-1.87), 0.171.28 (0.80-2.05), 0.30
VEGF 405G/C
    GGReferenceReferenceReferenceReference
    GC0.94 (0.68-1.30), 0.700.76 (0.33-1.78), 0.531.11 (0.52-2.37), 0.790.91 (0.65-1.26), 0.57
    CC0.80 (0.46-1.41), 0.450.73 (0.21-2.56), 0.620.91 (0.38-2.15), 0.820.79 (0.47-1.34), 0.38
VEGF 936C/T
    CCReferenceReferenceReferenceReference
    CT0.67 (0.45-0.99), 0.040.93(0.38-2.26), 0.870.54 (0.25-1.16), 0.110.63 (0.42-0.93), 0.02
    TT0.13 (0.02-0.94), 0.040.15 (0.02-1.18), 0.07
    T/−0.60 (0.41-0.89), 0.010.93(0.38-2.26), 0.870.44 (0.21-0.92), 0.030.56 (0.38-0.84), 0.005
  • * Adenocarcinoma and squamous carcinoma subgroups adjusted for age, gender, performance status, and disease stage. Lymph node–negative and lymph node–positive/metastatic subgroups adjusted for age, gender, and performance status.

  • Too few patients/events to analyze.